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ABSTRACT
This report looks into the administering process of vaccines within the United States and the method designed to aid the
decision-makers' process. The study method is based on a quantitative representation in which vaccine candidates are
administered. The procedure utilizes the corresponding (incomplete) data that could theoretically be used in other decisionmaking methods. The information provided by the vaccine manufacture is somewhat vague. The process entails predicting the
future and gaps. The study interview 1200 vaccinated patients to give an opinion based on the patients.
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AN INVESTIGATION INTO THE VACCINE FOR
COVID-19 WITHIN THE UNITED STATES
Despite the skepticism with which Covid-19 was received,
the disease has proven to be very resilient, affecting
millions of people globally. In the midst of the confusion
about the disease, Research Institution scientists were able
to show how the disease was expanding in the United
States and to make predictions about how the death toll
would rise. The researchers described the disease strain's
propagation, stating that it starts like the common flu,
sharing its symptoms with the usual flu. However, instead
of disappearing like other flu forms, the disease persisted
and made the victims feel tired and hot. Another common
symptom was a feeling of shortness of breath. Research
Institution interviewed ten patients who had survived the
disease, and they revealed that the disease affected their
nervous systems and went on for about two weeks
(Obasun, 2020a). The disease even affected those who had
generally been healthy all their lives. Research Institution
described how the disease arrived in the USA and how it
spread quickly to cover multiple states. According to the
research, the patients had to stay in isolation from their
loved ones to avoid infecting them with the deadly disease.
The article described how the virus originated from
Wuhan, China, and moved to the United States by January
20, 2020. However, the disease might have arrived earlier
than that. What started as the small flu in a distant place
managed to spread beyond China into other parts of the
world, including the US (Obasun, 2020a). Thanks to the'
research and development, different versions of the Covid19 vaccine have been developed and are undergoing
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human trials. Some have produced up to 95% effectiveness
against the current strain of the virus. However, the
summer made the Covid-19 strain weaker and less fatal.
The number of deaths resulting from the virus was
projected to be much higher than the Spanish flu epidemic
(Obasun, 2020a). However, due to the warm temperatures
during summer, the disease trait has not reached its
predicted fatality rate because the virus was made weaker
during summer. However, with the onset of the winter of
2020, the covid-19 virus is expected to become much
stronger during December 2020, January, and February
2021.
According
to
data
obtained
from
Researchinstitution.org, cold temperatures of winter are
expected to make the virus strain to mutate and become
more dangerous (Obasun, 2020b). Even though vaccines
have been manufactured and have already passed the
initial stages of the human trial, they may not be effective
against the mutated version of Covid-19, expected to be
named the Covid-20 by scientists.
According to an interview conducted by Research
Institution, 1200 were supposed to take the Covid-19
vaccine between August and September 2020; the vaccine
is proving strong against the Covid-19 virus (Obasun,
2020b). However, the manufacturers and scientists have
not considered the possible mutation of the virus so that it
may become stronger during the cold temperatures in the
winter months of December, January, and February.
Research Institution originally published the findings of
the mutation of Covid-19 into a more potent strain that
could defeat the vaccines that have been manufactured.
The research conducted by the Research Institution has
1
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shown that the current vaccines could be ineffective since
the disease is most likely going to mutate into a stronger
trait leading to reinfections at a higher rate than the one
that has already been experienced.
The occurrence of reinfection can only be confirmed
through a gold-standard confirmation of SARS-CoV-2
reinfection. This confirmation will require the detection of
the virus within two different time periods and conducting
genetic sequencing to confirm that the virus is actually
mutating. In October 2020, the CDC developed a common
investigation protocol that is to be used in investigating the
suspected SARS-CoV-2 reinfection. It is meant to support
a common public health study into the suspected
resurgence of Covid-19 reinfections in various
jurisdictions (CDC, 2020). To confirm that reinfection has
actually taken place, the researchers must conduct
advanced laboratory diagnostics and build upon the plan to
implement the protocol. It is also possible to develop a
locally adapted version of the protocol, but the specimens
have to support the laboratory networks. Once the data has
been collected through the use of the CDC developed
protocol, it will be used to identify potential reinfection
cases and promote the advancement of the understanding
of the SARS-CoV-2 epidemiology and make informed
public health response in the future. Patient symptomology
and epidemiologic links could provide the required
laboratory-based parameters for differentiating the
possibility of SARS-CoV-2 reinfection from the persistent
viral carriage. However, it would be impossible to confirm
reinfection in the absence of clinical specimens that were
obtained during the first COVID-19 illness.
Many other human coronaviruses (HCoVs) have been
known to lead to reinfections. According to a study in
Kenya, between 4 and 21 percent of people infected by the
endemic coronaviruses like NCoV-NL63, HCoV-229E
and HCoV-OC43 have had two or more infection episodes
with a similar virus species within a period of six months.
In another study in which a rise in antibodies was used as
a proxy for reinfections, it was discovered that reinfections
could actually take place within a median of six months
but could take place as early as half a year after the first
infection. There is, however, minimal information about
the durability of immunity to SARS-CoV-2. For instance,
it has been documented in South Korea that the COVID19 cases that had been undetectable by the RT-PCR could
later be tested and found to be positive by the same RTPCR within a 35-day time span. This was attributed to the
presumption that there were incomplete or defective viral
genomes, which means that reinfection was undetectable
within the time frame. To establish a common
understanding of Covid-19 reinfections, CDC (2020)
recently developed a standard investigation protocol to
identify cases with a high index of suspicion for
reinfection. The CDC also provided suggestions for paired
specimen testing.
In light of the expected reinfection by the mutated Covid20 virus, it is essential to consider the safety measures
suggested by Obasun (2020b). According to the research
done by Research Institution, there is a need to restrict
movement and discover vaccines and prescription
medication for those already infected. The Covid-19
vaccine discovery has been a significant breakthrough, but
the possibility of Covid-20 is quite worrying. The case is
even more bizarre considering the immunity of the people
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in the United States. According to Obasun (2020b), the
immunity in the US is much lower than that in China, from
where the disease originated. This is mainly because of
Americans' health conditions, including diabetes, obesity,
and other immunity-lowering conditions.
Through research, it has been discovered that people often
develop antibodies to particular diseases after they have
been exposed to such illnesses, which can help them avoid
becoming re-infected by the same disease trait (Obasun,
2020b). People in tropical areas are often exposed to
tropical diseases, which are useful in helping them
accumulate T-cells. The T-cells are responsible for helping
the body to fight off infections like malaria. The
coronavirus has, however, proven much stronger than the
T-cells. With very low levels of T-cells and very low
winter temperatures, it is expected that Americans could
suffer a major blow from the mutated version of Covid-19.
The Covid-19 has infected more than 12 million people
globally and has led to more than half a million deaths. The
disease has also caused an economic toll of trillions of
dollars. The disease has affected some of the most
vulnerable members of society, including those aged 65
years and more, people who are economically deprived,
and those living with underlying health conditions.
Considering its effects and the rate at which it is still
spreading, there is an urgent need to make vaccines
available to the public to help eliminate the complications
and deaths that are taking place as a result of the
transmission of the disease.
Scientists and major research institutions have been
conducting extensive research to find an effective vaccine
against the disease. An mRNA SARS-CoV-2 vaccine was
recently developed and successfully taken through a phase
1 trial in which the researchers were interested in the
immunogenicity of the vaccine. The trial involved fortyfive healthy adults aged between 18 and 55 years (Doshi,
2020). The individuals were injected with the candidate
vaccine at different doses, 25 μg, 100 μg, or 250 μg, which
was given in the form of two vaccinations 28 days apart. It
is remarkable how quickly the vaccine has been
developed, and its effectiveness is promising.
As people continue to enroll for phase 3 of the SARSCoV-2 vaccine and the target enrolments have been
achieved, there is hope that there could be an end to the
COVID-19 pandemic. It has been established that no
approvals will be made until the vaccines are proven to be
safe and effective (Heaton, 2020). However, the current
tests have not even come close to ensuring that a vaccine
is both safe and effective. This makes it quite doubtful
whether there is to be any further breakthrough (Kagina,
2020). Considering the projections made by Research
Institution that the virus could be mutating to become more
severe at the end of 2020 and the beginning of 2021, the
possibilities are even slimmer. The disease could become
more deadly and lead to even more infections and deaths
in 2021 than it has been in the past (Mintzes, Lexchin,
Chiu, & Parker, 2020). Therefore, there is a need to
exercise more caution, and research needs to be more
rigorous to discover better ways of dealing with a mutated
version of the virus.
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